





### **Disclaimer**



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

# **Speakers Today**



Ricardo Naranjo Fernandez Interim CEO



Jossue Yesquen Lihim IRO




### Key Developments YTD 3Q 2024














• September 2024 delivered a record monthly EBITDA of USD 30.7M, the highest in Camposol's history. EBITDA YTD through 3Q 2024 increased by 96% compared to the same period in 2023, driven by improved operational strategies and favorable market dynamics. On an LTM basis, EBITDA at the end of 3Q 2024 reached USD 159.8M, surpassing the previous twelvementh record of USD 152.8M set in 2018.



- Our strategic decision to conduct early pruning in blueberries allowed us to secure early-season volume, enabling optimized fruit allocation, maximum profitability, and strengthened retailer partnerships during 3Q. Peru's avocado harvest volume decreased from last year, mainly due to early-year higher temperatures. However, the high export quality allowed Camposol to achieve premium market pricing.
- We successfully concluded a three-year collective bargaining agreement with company unions, a key milestone achieved through continuous collaboration and open communication with our workforce.
- Debt restructuring efforts continued in 3Q 2024, including bond repurchases that contributed an additional USD 1.5M nominal value reduction. Additionally, a local bank leaseback agreement for USD 15M supports our commitment to managing short-term debt reductions expected to continue into 4Q.




# Operational overview YTD 3Q 2024 - Key metrics YTD



#### Volume Sold (MT)






Volume sold during the first nine months of 2024 shows an 18% decrease compared to the same period last year, mainly driven by declines in the volume of mangoes, avocado, grapes and tangerine, partially offset by a higher volume sold of blueberry.

### Revenue USD (MM)






Revenue during the first nine months of 2024 was 14% higher compared to the same period last year, mainly driven by higher revenue of blueberries and avocados, off set by lower revenue of grapes and tangerines.

### EBITDA USD (MM)






EBITDA generated during the first nine months of 2024 was USD 102.6 nearly matches that of our entire performance in 2023. 3Q LTM EBITDA reached USD 159.8M, which is 46% higher compared to the FY 2023.

#### **Net Income USD (MM)**






The net profit generated as of closing 3Q 2024 reached USD 32.7M, 63% higher than the generated in full year 2023.

# Operational overview YTD 3Q 2024 - Crop performance YTD





**Total has: 2,147** 

# Operational overview YTD 3Q 2024 - Crop performance LTM







### Volume Sold (MT)














**Planted Hectares** 


o Peru: 2,691

50 Own Var:




Total: 2,741





























**Total has:** 4,665









1,129 o Peru:

Uruguay: 869


Chile: 149

Total has: 2,147



# Operational overview YTD 3Q 2024 - Quarterly EBITDA reconciliation





Blueberry: Our campaign kicked off robustly, with prices in 3Q 2024 up 26% from 3Q 2023. By executing timely pruning, we ensured a solid volume at the start of the season, enabling us to capture higher prices.


Avocado: Following a successful first Colombian campaign, the Peruvian avocado campaign closed September with strong performance, achieving a 36% higher price than in the same period of 2023.

Mango: Despite a decline in Peruvian mango production, Camposol demonstrated resilience and adaptability, achieving a 64% price increase.

Selling expenses: The decrease, particularly in freight costs which saw a 32% reduction compared to first nine months of 2023, is primarily attributed to the improved average freight rate and lower volume.

### Operational overview YTD 3Q 2024 - Cash flow





As of the close of September, collections and supplier payments are managed based on cash inflows from the Peruvian avocado campaign and the start of the 2024-2025 blueberry season, with the bulk of collections expected in 4Q 2024.

CAPEX: Our capital expenditures focus on short-term growth initiatives and risk mitigation projects, including the ongoing construction of water reservoirs and a new solar power plant in Viru.

We completed the payment of declared dividends, which were largely used to offset intercompany loans issued between 2023 and 2024.

Bond buyback program: disbursing USD 21.8 million in 2024. Starting 4Q 2023, when we did the first buyback, through the end of 3Q 2024, we have repurchased USD 38.2 million in nominal value.




## Operational overview YTD 3Q 2024 - Leverage and Debt profile



#### **Debt Profile**

We continued our debt reduction strategy with an additional USD 1.5M nominal decrease through bond repurchases and secured a new USD 15M leaseback arrangement.


We began reducing short-term debt, and with collections starting at the end of 3Q, we are well-positioned to continue executing our debt reduction plan through Q4 2024.



### Total financing credit lines vs short term debt

☐ Available credit line ☐ Working capital short term debt

Available credit line / WKSTD



With a cash balance and committed credit lines totaling USD 85M, we currently cover 56% of our short-term debt obligations.


When considering undrawn financing lines, our total available funds reach USD 118M, covering 78% of our short-term debt and providing significant flexibility to support business growth.

# Operational overview YTD 3Q 2024 - Leverage and Debt profile




### **Debt history**

Total debt remains similar to the close of 2Q 2024, with a shift from short-term working capital lines to longer-term debt. Throughout the past nine months, we have strengthened our banking relationships, opening new working capital lines with three additional financial institutions and increasing authorized lines with existing partners—a positive reflection of the company's performance.



### **Net Debt / EBITDA**



Our Net Debt/EBITDA ratio reached 3.31x, below our target, driven by strong operational performance and effective debt management over the past year and a half.



# Financial Statements YTD 3Q 2024 - Income Statement



	For the period ended	
	30.09.2024	30.09.2023
Revenue	302,016	264,607
Cost of sales	(187,723)	(190,899)
Gross profit before adjustment for biological assets	114,293	73,708
Net adjust. from change in fair value of bio.assets	3,426	(2,983)
Profit after adjustment from biological assets	117,719	70,725
Selling expenses	(32,606)	(43,656)
Administrative expenses	(18,979)	(16,248)
Other expenses	(3,592)	(2,652)
Otherincome	2,980	1,724
Net foreign exchange transactions gains (losses)	(1,535)	(3,120)
Operating profit	63,987	6,773
Share of gain (loss) of associated companies	(87)	141
Finance income	8,162	249
Finance costs	(34,151)	(35,651)
Profit (loss) before income tax	37,911	(28,488)
Income tax	(8,431)	(875)
Deferred income tax	3,264	5,717
Profit (loss) for the period	32,744	(23,646)
BITDA before fair value adjustment	102,599	52,257

# Financial Statements YTD 3Q 2024 - Cash Flow



	For the period ended	
	30.09.24	31.12.23
Cash flow from operating activities		
Collections	322,913	494,563
Payment to suppliers and employees	(275,989)	(354,732)
Interest paid	(25,966)	(43,479)
Income tax paid	(5,831)	(8,297)
Custom duties refund collections	1,968	3,030
Other collections / payments	2,883	
Other payments	(1,644)	(1,702)
Net cash (used in) provided by operating activities	18,334	89,383
Cash flow from investing activities		
Purchases of property, plant and equipment	(6,413)	(13,636)
Investment in biological assets	(13,270)	(35,779)
Purchases of intangibles, excluding goodwill	(710)	(33,779) $(1,424)$
Loans granted to related parties	(8,388)	(10,000)
Loans payment to related parties	19,444	(10,000)
Proceeds from sale of property, plant and equipment	909	196
Net cash used in investing activities	(8,428)	(59,450)
The Court area in investing activities	(0, 120)	(57, 155)
Cash flow from financial activities		
Bank loans proceeds	216,192	589,993
Bank loans payments	(180,423)	(677,360)
Dividends distribution	(20,844)	-
Principal elements of lease liabilities payments	(2,673)	(9,952)
Transaction costs	(723)	(3,620)
Leaseback proceeds	8,972	82,499
Principal elements of leaseback payments	(6,715)	(8,989)
Payments of long-term debt	(22,808)	(5,823)
Net cash provided by financial activities	(9,022)	(33,252)
No. (decree) No. (decree)	00.4	(2.240)
Net (decrease) increase in cash during the period	884	(3,319)
Cash and cash equivalents at beginning of period	23,903	27,222
Cash and cash equivalents at end of period	24,787	23,903

# Financial Statements 3Q 2024 - Balance Sheet



	For the period ended	
	30.09.2024	31.12.2023
Assets		
Non-current assets		
Property, plant and equipment, net	716,272	740,801
Right of use asset	31,492	36,379
Investments in associated companies	4,368	4,852
Intangibles	11,915	12,885
Deferred income tax	18,477	14,014
Other accounts receivable	408	408
	782,932	809,339
Current assets		
Prepaid expenses	1,246	1,126
Current portion of biological assets	183,769	165,106
Inventories	63,659	50,922
Other accounts receivable	20,002	32,166
Trade accounts receivable	24,861	45,303
Cash and cash equivalents	24,787	23,903
	318,324	318,526
Total assets	1,101,256	1,127,865

	Paulia naniad andad	
	For the period ended 30.09.2024 31.12.2023	
Faviley and liabilities	30.09.2024	31.12.2023
Equity and liabilities		
Capital and reserve attributable to		
shareholders of the Company	10.000	10.000
Share capital	10,000	10,000
Revaluation of assets	172,497	172,497
Retained earnings	115,684	118,490
	298,181	300,987
Minority interests	- 997	- 994
Total equity	297,184	299,993
Non-current liabilities		
Long-term debt	317,621	346,639
Lease liability	68,002	70,261
Deferred income tax	124,365	123,166
Other payables	1,398	1,398
	511,386	541,464
Current liabilities		
Accounts payable to related companies	31	31
Current portion of long-term debt	3,702	8,562
Current portion of lease liability	20,215	22,130
Trade payables	82,045	103,756
Other payables	24,849	27,168
Bank loans	161,844	124,761
	292,686	286,408
Total liabilities	804,072	827,872
Total equity and liabilities	1,101,256	1,127,865

# Strategic priorities 2024





Increase yield per hectare

Expand our own blueberry variety.



Focus on controlling and reducing logistic costs

Ocean freight.



Strengthen commercial leverage

Expand penetration in retail channel.

Continue developing the Asian market



Closely monitor longterm investments in Colombia, Uruguay, Chile and Mexico.



Reduce debt level

**Prioritize liquidity** 

Maximize liquidity sources.

Only maintenance and short-term growth capex.

.







Búscanos como CamposolCares en:







Búscanos como Camposol en:



Para más información por favor conectarse a www.camposol.com.pe

For more information please log into www.camposol.com.pe